Remon, J., Esteller, L., & Taus, Á. (2019). Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: Evidence to date. Cancer Manag Res.
Chicago Style CitationRemon, Jordi, Laura Esteller, and Álvaro Taus. "Nivolumab Plus Ipilimumab Combination Therapy for the First-line Treatment NSCLC: Evidence to Date." Cancer Manag Res 2019.
MLA CitationRemon, Jordi, Laura Esteller, and Álvaro Taus. "Nivolumab Plus Ipilimumab Combination Therapy for the First-line Treatment NSCLC: Evidence to Date." Cancer Manag Res 2019.
Warning: These citations may not always be 100% accurate.